

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 16, No. 6

March 24th, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- ASCO's *State of Cancer Care in America*
- ICER seeks comments on ovarian cancer
- ANCO's *Hematologic Malignancies Updates*
- ANCO Event at ASCO's Best of ASCO

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members. The next regular *ANCO FAX News* will be published on April 14th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The ANCO FAX News has information for every member of your practice or organization. Pass it along!

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

The *United States* cancer care delivery system is undergoing profound changes to better meet the needs of people with cancer, but persistent hurdles threaten to slow progress, according to ASCO's fourth annual *State of Cancer Care in America* report. The report is published in the *Journal of Oncology Practice* and was presented at a briefing on *Capitol Hill*. A summary of the report is available at www.asco.org/advocacy-policy/asco-in-action/us-cancer-care-system-poised-transformation-challenges-loom-large.

The *Institute for Clinical and Economic Review* (ICER) draft scoping document on treatments for ovarian cancer is open for comments until March 27th. For more information, please visit icer-review.org/material/ovarian-cancer-draft-scope/?utm_source=Ovarian+Draft+Scope&utm_campaign=Ovarian+scope&utm_medium=email.

The Medicare Quality Payment Program (QPP), established by the Medicare Access and CHIP Reauthorization Act (MACRA) began on January 1st. This year is a transition year meaning you can "pick your pace" when implementing QPP in your practice. For more information and access to ASCO's QPP tools, educational materials, and resources, go to www.asco.org/advocacy-policy/asco-in-action/macra-implementation-has-begun-will-you-avoid-4-percent-reimbursement.

CMS has extended the data submission deadline for the EHR reporting mechanism of the 2016 Quality Reporting Document Architecture (QRDA) for the Physician Quality Reporting System (PQRS) program. Individual eligible professionals (EPs), PQRS group practices, qualified clinical data registries (QCDRs), and qualified EHR data submission vendors (DSVs) now have until Friday, March 31st to submit 2016 EHR data via QRDA. Go to

www.asco.org/advocacy-policy/asco-in-action/2016-pqrs-data-submission-deadline-ehr-reporting-mechanism-extended-for-more-information.

CMS has announced that it is now accepting hardship exceptions from the meaningful use requirements of the EHR incentive payment program for the 2016 reporting year. Physicians who can show that demonstrating meaningful use would result in a significant hardship can apply for a one-year exception and avoid a negative payment adjustment in 2018. The deadline is July 1st. Go to www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/PaymentAdj_Hardship.html for more information and applications.

The California Department of Health Care Services (DHCS) has announced that it will extend the deadline for Medi-Cal meaningful use reporting for the 2016 program year to May 2nd. After that date, DHCS will only accept 2017 attestations.

CMA, MOASC, and State Legislative & Regulatory Issues

The *California Oncology Political Action Committee* (or CalCancerPAC), formed by ANCO and MOASC, supports candidates sensitive to the needs of hematologists/oncologists and people living with cancer in California. ANCO membership dues include a contribution to CalCancerPAC.

Sacramento can be a dangerous place for doctors. Many bills impacting medicine wind their way through the *Capitol* on their journey to the *Governor's* desk. And, many of these bills threaten the medical profession with the backing of powerful lobbyists and PACs. It's critical that physicians have an advocate at work for them every day and who knows how to speak on their behalf. That advocate is the *California Medical Association* (CMA). While physicians keep a close eye on their patients, CMA is keeping a close eye on those bills...and more. Got payment delays? Feeling victimized by payers and overwhelmed by the process? Don't let the health plans mistreat you. The CMA's *Center for Economic Services* (CES) has a team of reimbursement specialists available to assist ANCO's CMA members experiencing payment problems with third-party payers. For membership, please call (916) 551-2042; for reimbursement assistance, please call

CMA's *Reimbursement Helpline* at (888) 401-5911.

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe.

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) *Medicare Administrative Contractor (MAC)*. Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—Revised CMS-855O Application: Enrollment Solely to Order, Certify, or Prescribe; Connected Care: New Educational Initiative to Raise Awareness of Chronic Care Management; Quality Payment Program: New Materials
- Claims, Pricers, and Codes*—Chronic Care Management Payment Correction for RHCs and FQHCs
- Events*—Open Payments: Prepare to Review Reported Data Call-April 13;
- Publications*—Provider Enrollment Revalidation: Cycle 2 MLN Matters Article-Revised; Medicare-Required SNF PPS Assessments Educational Tool-Revised; Items and Services Not Covered under Medicare Booklet-Revised
- ASC Payment System-April 2017 Update CR9998
- Self-Service Reopenings Through Noridian Medicare Portal-More Options Available
- DMEPOS Fee Schedule-April 2017 Update
- Controlled Substance Monitoring and Drugs of Abuse Testing-R1

- Provider Enrollment Revalidation-Cycle 2-Revised SE1605
- Appealing Demand Letters
- Claim Denied for Duplicate or Bundling? Noridian Medicare Portal Has the Answer
- Positron Emission Tomography Scans Coverage-R9

Noridian/JEMAC's Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at www.edissweb.com/cgp/news/index.html.

Forthcoming Noridian/JEMAC meetings/workshops include:

- Reopenings (March 28)
- CMS-1500 Claim Form Submission (March 29)
- *Noridian* Medicare Portal Registration for Part B Providers (April 4)
- Modifier 59 (April 12)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more information and to register.

According to *Noridian/JEMAC*, their coverage edits for HCPCS code G0498 currently only covers the code when used with trabectedin (J9999) and this is an error. They are currently updating their coverage edits to include additional drugs (J codes) that could be infused via pump over an extended period-of-time. A new coverage article is being prepared and will be published by *Noridian/JEMAC* very soon. It will include several additional covered drugs, including J9000 (doxorubicin), J9181 (etoposide), J9190 (flourouracil), and J9371 (vincristine). Additional drugs will be added as necessary. Depending on the number of impacted claims, a mass adjustment may be ordered. Until then, practices may appeal and the appeal will be overturned.

Beginning April 1st, *Noridian/JEMAC's* Medicare portal will require multi-factor authorization process for users. This adds a second layer of security to your *Noridian/JEMAC* account. Go to med.noridianmedicare.com/web/jeb/article-detail/-/view/10546/multi-factor-authentication-required-on-noridian-medicare-portal-beginning-april-1-2017 for more information.

Anthem Blue Cross is implementing important changes to its national drug list (formulary) effective April 1st. Review these changes at file.anthem.com.s3-website-us-east-1.amazonaws.com/64774CAEENABC.pdf.

Anthem Blue Cross has announced that effective May 15th, Myriad Genetic Laboratories will no longer be an in-network laboratory provider. A complete list of in-network participating laboratories may be obtained online at www.anthem.com/ca > Provider > Find a Doctor.

UnitedHealthcare's commercial reimbursement policies will begin requiring biosimilar biological products to include a modifier that identifies the manufacturer of the specific product for dates of service on or after June 1st. Specifically, the modifier for Q5101 (filgrastim) Zarxio will be ZA (Novartis/Sandoz) and the modifier for Q5102 (infliximab) Inflectra will be ZA (Pfizer/Hospira).

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

SAVE THE DATE

ANCO's 2017 Hematologic Malignancies Updates

ANCO is organizing a series of *Hematologic Malignancies Updates* in 2017. The first *Update* will take place on May 6th at the *Sacramento Hyatt Regency* with Mehrdad Abedi, M.D., *University of California, Davis*, Sandy Wong, M.D., *University of California, San Francisco*, and Julian Davis, M.D., *University of California, Davis*. The latest research on novel treatment modalities for hematologic malignancies, myeloma, and amyloidosis, along with case studies for these diagnoses will be presented. These updates are supported by *Janssen Biotech*, *Merck*, *Pfizer Oncology*, and *Pharmacyclics*. Watch for a meeting announcement in late March.

SAVE THE DATE

ANCO Event at ASCO's Best of ASCO 2017

ANCO's *ASCO Highlights* will not take place in 2017 in lieu of our encouragement of members to attend ASCO's *Best of ASCO* in San Francisco (west-boa.asco.org; June 16-17th). However, ANCO will host an event on June 15th entitled

The State of Cancer Care with Margaret Tempero, M.D., *University of California, San Francisco*, at the *San Francisco Marriott Marquis*. Watch for a meeting announcement in April.

Additional Education Meetings

March 28th

Progress in the Treatment of Follicular Lymphoma
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 29th-31st

Cancerscape: Business & Policy, Value & Quality—ACCC 43rd Annual Meeting
Association of Community Cancer Centers
Washington, DC
(www.accc-cancer.org/meetings/AM2017.asp)

April 3rd

Advances in the Treatment of Colorectal Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

April 5th

Progress in the Treatment of Oral and Head and Neck Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

April 6th

Update on Chronic Lymphocytic Leukemia (CLL)
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

April 20th-22nd

Cancer Metastasis through the Lymphovascular System: Biology & Treatment—7th International Symposium
Sentinel Node Oncology Foundation
San Francisco
(www.cancermetastasis.org)

April 27-28th

The 2017 Community Oncology Conference: Fueling the Cancer Moonshot
Community Oncology Alliance
Washington, D.C.
(<http://www.coaconference.org>)

April 28th

The New Age of Molecular Testing and Targeted Therapies in Lung Cancer
ACCC & AMP
(<https://attendeegotowebinar.com/register/2573310585943935235>)

May 2nd

Update on Advanced Ovarian Cancer

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

May 5th

Advances in the Treatment of Renal Cell Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

May 18th

Progress in the Treatment of Multiple Myeloma
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

June 29-30th

POLST: It Starts With A Conversation
Coalition for Compassionate Care of California
Long Beach
(coalitionccc.org/training-events/polst-education/)

September 27-28th

ASCO Advocacy Summit 2017: Lead, Engage, Influence
ASCO
(www.surveymonkey.com/r/AdvocacySummit2017)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

Board of Directors

The ANCO *Board of Directors* teleconferenced on March 21st to discuss and/or act upon the following:

- ANCO's financial reserves and investments
- California legislative and regulatory updates

Contact the ANCO office for additional information on any of these items.

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The next regularly scheduled ANCO *Board of Directors* meeting is scheduled for April 29th.

Please call José Luis González, ANCO Executive

Director, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

The *Living With Cancer Series*, a collection of films produced by ANCO member Alan M. Kramer, M.D., is intended to inspire and educate cancer patients, caregivers, and health professionals dealing with all forms and stages of cancer. Three documentaries are now available—*Living with Breast Cancer: The Children's Story*, *Living with Lung Cancer: The Wells Whitney Story*, and *Living with Breast Cancer: The Spouse's Story*—and another is in production—*Living with Cancer: Our Pets, Our Saviors*. Learn more at livingwithcancerseries.com.

A current *Directory of Members* is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Marin Cancer Care*, *Pacific Cancer Care*, *Palo Alto Medical Foundation*, and *Valley Medical Oncology Consultants* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*

- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Agendia • Alexion Pharmaceuticals
AMGEN • ARIAD Pharmaceuticals
Astellas Oncology • AstraZeneca
Bayer Healthcare Pharmaceuticals
bioTheragnostics
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Dendreon • Eisai • EMD Serono • Exelixis
Foundation Medicine
Genoptix Medical Laboratory
GenPath Oncology • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Infinity Pharmaceuticals
Ipsen Biopharmaceuticals
Janssen Oncology • Jazz Pharmaceuticals
Lilly Oncology • Merrimack Pharmaceuticals
Medivation • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Pfizer Oncology
Pfizer US Biosimilars • Pharmacyclics
Prometheus Laboratories, Inc.
Sandoz Biopharmaceuticals • Sanofi Genzyme
Seattle Genetics • Taiho Oncology
Takeda Oncology • Tesaro • TEVA Oncology*

We especially wish to thank and welcome *Agendia, bioTheragnostics, EMD Serono, and Pfizer US Biosimilars* as new Corporate Members for 2017. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

Boehringer Ingelheim Pharmaceuticals informs ANCO that the *United States Food and Drug Administration* has approved Gilotrif for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors

have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

Celgene informs ANCO that the *United States Food and Drug Administration* has approved Revlimid as maintenance therapy for multiple myeloma patients after autologous hematopoietic stem cell transplantation (auto-HSCT).

EMD Serono informs ANCO that the *United States Food and Drug Administration* has approved Bavencio for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).

Lilly Oncology informs ANCO it has released a new vial size for Lartruvo that will significantly reduce wastage. Lartruvo is now supplied as 190mg/19mL and 500mg/50ML (10mg/mL), single-dose vials. The NDC for the new, 190mg vial size is 0002-7190-01.

Merck informs ANCO that the *United States Food and Drug Administration* (FDA) has approved Keytruda for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL) or who have relapsed after three or more prior lines of therapy. Additionally, *Merck* has recognized *Hematogenix Laboratory Services* as one of the national reference laboratories offering FDA-approved PD-L1 companion diagnostic assay PD-L1 IHC 22C3 pharmDx for Keytruda.

Novartis Oncology informs ANCO that the *United States Food and Drug Administration* has approved Kisqali in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

Publications, Resources, Services, & Surveys

To better understand the contributions of advanced practice providers (APPs) working in oncology, ASCO is partnering with four other healthcare provider organizations (*Advanced Practitioner Society for Hematology and Oncology, American Academy of PAs, Association of Physician Assistants in Oncology, Oncology Nursing Society*) to conduct a survey that will examine the specific roles and responsibilities of APPs within the

cancer care delivery team. Read more about the survey at www.asco.org/advocacy-policy/asco-in-action/new-survey-advanced-practice-providers-oncology-launched. If you are contacted to participate, you will receive the survey via postal mail or an e-mail from ASCO.survey@jacksonsurveys.com. ASCO urges members to complete the survey and return it as instructed by March 29th. The survey should take 20 minutes or less to complete.

ASCO's Clinical Affairs Department is dedicated to providing services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/asco-in-action/asco's-clinical-affairs-department-opens-new-survey-practice-operations.

ASCO's 2017 Quality Training Program, a six-month course in data-driven quality improvement, will now take place in two locations—Dallas and Portland. The session dates for Portland are April 20th-21st, June 28-29th, and October 18th. To learn more about and apply to participate in the Program, visit www.asco.org/training-education/professional-development/quality-training-program.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Go to www.asco.org/PracticeNET for more information.

The March 2017 issue of ASCO's Journal of Oncology Practice (JOP) is available online and features articles entitled *USP: United in Safeguarding Patients, Personnel, and Providers; Payer View of High-Quality Clinical Pathways for Cancer; Perspectives on the Implementation of an Ethical Rapid Learning Health System; Patient Perspectives on the Ethical Implementation of a Rapid Learning System for Oncology Care;*

Qualitative Study of Oncologists' Views on the CancerLinQ Rapid Learning System; Transparency of Industry-Sponsored Oncology Patient Financial Assistance Programs Using a Patient-Centered Approach; Do Patients and Oncologists Discuss the Cost of Cancer Treatment? An Observational Study of Clinical Interactions Between African American Patients and Their Oncologists; Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: 2016 American Society of Clinical Oncology Clinical Practice Guideline Update Summary; American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology. Visit jop.ascopubs.org for more information.

ASCO and Innovative Oncology Business Solutions (IOBS) have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer. ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA and will be available across the country starting on January 1st, 2017. ASCO is now recruiting practices for the fee-based 2017 ASCO COME HOME program. For more information, please contact Elaine Towle (elaine.towle@asco.org). Learn more about ASCO's physician payment reform efforts at www.asco.org/advocacy-policy/policies-positions-guidance/coverage-reimbursement/physician-payment-reform.

On March 14th, the Spring Round for ASCO's QOPI opened for reporting. The Spring Round will close on May 9th. Learn more at www.asco.org/advocacy-policy/asco-in-action/qopi-spring-round-reporting-opens-march-14-register-now.

A new collaboration between ASCO and the American Board of Internal Medicine (ABIM) enables participants of ASCO's Quality Oncology Practice Initiative (QOPI) to receive Maintenance of Certification (MOC) Practice Assessment points from ABIM. For more information on ABIM MOC, eligibility and requirements, please visit university.asco.org/practice-assessment-activities.

In 2017, practices will also be able to use the QOPI platform to meet the MIPS reporting requirement of one measure through manual reporting. While one measure is the minimum

requirement to avoid the 2019 penalty, ASCO encourages all practices to report on at least four measure to become fully acquainted with the system and ensure that the CMS requirements are met.

ACCC's online *Oncology Drug Database* provides quick access to information on oncology drug coding, billing, and reimbursement at www.accc-cancer.org/drugdatabase/.

ACCC's enhanced set of *Financial Advocacy Network* resources are at www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp. This "one-stop" destination for comprehensive financial advocacy information includes online training materials, practical financial advocacy tools, peer-to-peer networking, and more.

ACCC's 2017 *Patient Assistance and Reimbursement Guide* is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. Visit www.accc-cancer.org/publications/pdf/Patient-Assistance-Guide-2017.pdf to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at acc-fan-app.org. **ASH also has a webpage (at www.hematology.org/Clinicians/Drugs/Programs/) that provides a consolidated list of resources for hematologists and patients trying to access high cost hematologic drugs.** And, at NCCN's **Reimbursement Resource Room** (www.nccn.org/reimbursement_resource_room/default.asp) **you can select a cancer diagnosis or supportive care indication and learn about reimbursement help and services available to you.** Finally, ***assistPoint* is your website for complimentary one-stop cancer Patient Assistance.** You can search by generic, brand name, manufacturer, or diagnosis for the enrollment forms you need; get enrollment form PDFs for cancer drugs; get NDC numbers for all of those drugs; find the HCPCS J-code for each drug; get coding and billing guidelines for many drugs; and, learn more about the drugs you give. Go to www.assistpoint.com to learn more.

To support clinical decision-making around the

use of radiation therapy in patients with cancer, NCCN has launched the *NCCN Radiation Therapy Compendium*. The radiation therapy recommendations contained in the *Compendium* are derived directly from the library of NCCN *Clinical Practice Guidelines in Oncology* which document evidence-based, consensus-driven management to ensure that all patients receive care most likely to lead to optimal outcomes. Learn more at www.nccn.org/about/news/newsinfo.aspx?NewsID=851.

NCCN has published and/or updated their *Clinical Practice Guidelines in Oncology and/or Drugs & Biologics Compendium* for breast cancer (V1.2017); chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; chemotherapy order templates); colon and rectal cancers (V2.2017 and V3.2017); hepatobiliary cancers (V1.2017); non-small cell lung cancer (V5.2017); palliative care (V1.2017); and, penile cancer (V2.2017). Go to www.nccn.org for more information. NCCN is pleased to offer pocket-sized versions of the NCCN *Clinical Practice Guidelines in Oncology* for a number of their guidelines at www.nccn.org/redirects/nicelines.asp?Type=general.

The *California Chronic Care Coalition* (CCCC) is on a mission to inform patients in California about their rights as health care consumers. Their website, mypatientrights.org, is an online resource to help patients identify when, why, and how to file a complaint with their health plan and/or the California *Department of Managed Health Care* (DMHC) to demand the care they need and deserve.

Individual Membership Dues for 2017

Second notices of membership renewal for 2017 were mailed to all members in early February. If you have not yet done so, then please return your 2017 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse manager contact(s). Those not renewing their membership by June 30th will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you do not receive or misplaced your membership dues renewal notice.